JP2022521208A5 - - Google Patents

Info

Publication number
JP2022521208A5
JP2022521208A5 JP2021548233A JP2021548233A JP2022521208A5 JP 2022521208 A5 JP2022521208 A5 JP 2022521208A5 JP 2021548233 A JP2021548233 A JP 2021548233A JP 2021548233 A JP2021548233 A JP 2021548233A JP 2022521208 A5 JP2022521208 A5 JP 2022521208A5
Authority
JP
Japan
Prior art keywords
nri
pharmaceutical composition
maoi
composition according
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021548233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521208A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018567 external-priority patent/WO2020168337A1/en
Publication of JP2022521208A publication Critical patent/JP2022521208A/ja
Publication of JP2022521208A5 publication Critical patent/JP2022521208A5/ja
Pending legal-status Critical Current

Links

JP2021548233A 2019-02-17 2020-02-18 うつ病及び他の障害の治療のための組成物及び方法 Pending JP2022521208A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806831P 2019-02-17 2019-02-17
US62/806,831 2019-02-17
PCT/US2020/018567 WO2020168337A1 (en) 2019-02-17 2020-02-18 Compositions and methods for treatment of depression and other disorders

Publications (2)

Publication Number Publication Date
JP2022521208A JP2022521208A (ja) 2022-04-06
JP2022521208A5 true JP2022521208A5 (cg-RX-API-DMAC10.html) 2023-03-01

Family

ID=72045151

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021548233A Pending JP2022521208A (ja) 2019-02-17 2020-02-18 うつ病及び他の障害の治療のための組成物及び方法

Country Status (7)

Country Link
US (1) US12465611B2 (cg-RX-API-DMAC10.html)
EP (1) EP3923919A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022521208A (cg-RX-API-DMAC10.html)
CN (1) CN113631157A (cg-RX-API-DMAC10.html)
AU (2) AU2020223284A1 (cg-RX-API-DMAC10.html)
CA (1) CA3130580A1 (cg-RX-API-DMAC10.html)
WO (1) WO2020168337A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4727545A2 (en) * 2023-06-16 2026-04-22 Neurawell Therapeutics Combination treatments for depression and other disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999382A (en) 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20040102440A1 (en) 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
EP1715843A1 (en) * 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
EP1737473A4 (en) 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
KR20080013853A (ko) 2005-02-23 2008-02-13 사이케노믹스, 인코퍼레이티드 복수매개물질 도파민 수송체 저해물질 및 이와 관련된 용도
CA2598838A1 (en) 2005-02-23 2006-08-31 Prexa Pharmaceuticals, Inc. Multimediator 5-ht6 receptor antagonists, and uses related thereto
KR20080003849A (ko) 2005-03-31 2008-01-08 아밀린 파마슈티칼스, 인크. 비만 및 섭식 장애의 조절, 예방 및 치료를 위한 조성물 및방법
JP2008538576A (ja) 2005-04-22 2008-10-30 ワイス クロマンおよびクロメン誘導体およびその使用
CN101198322A (zh) 2005-04-22 2008-06-11 惠氏公司 用于治疗或预防抑郁症的新治疗组合
JP2009531435A (ja) 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
AU2008226541B2 (en) * 2007-03-09 2013-05-09 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
ES2431570T3 (es) * 2007-05-07 2013-11-27 Chelsea Therapeutics, Inc. Droxidopa y composición farmacéutica de la misma para el tratamiento de los trastornos por déficit de atención
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US20110262442A1 (en) 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
US10463633B2 (en) 2010-04-23 2019-11-05 Kempharm, Inc. Therapeutic formulation for reduced drug side effects
US20130324609A1 (en) 2010-10-08 2013-12-05 University Of Utah Research Foundation Depression disorder therapeutics with creatine analogs
US20130217673A1 (en) 2012-02-22 2013-08-22 Warsaw Orthopedic, Inc Mixed monoamine reuptake inhibitor in a biodegradable polymer carrier
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
CA2899455C (en) 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
KR20230116948A (ko) 2016-03-10 2023-08-04 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
US10624939B2 (en) 2017-05-23 2020-04-21 Luke Klele Natural product compositions for treating or managing symptoms of ADD, ADHD, anxiety, and depression
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
CN111233737B (zh) 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途

Similar Documents

Publication Publication Date Title
JP2005506367A5 (cg-RX-API-DMAC10.html)
JP2009511618A (ja) 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用
EP1721607A1 (en) Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
JP2024540183A5 (cg-RX-API-DMAC10.html)
US20080014252A1 (en) Topical compositions with long lasting effect
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
JP2022153638A5 (cg-RX-API-DMAC10.html)
HUE029677T2 (hu) Készítmények centrálisan mediált émelygés és hányás kezelésére
RU97103563A (ru) Композиции длительного высвобождения венлафаксин гидрохлорида, композиция пленочного покрытия, способ обеспечения терапевтически активной концентрации венлафаксина и способ исключения нулевых и пиковых концентраций лекарственного средства
TWI312678B (en) Pharmaceutical composition comprising dapoxetine for treating sexual dysfunction
SK14612003A3 (sk) Použitie enantiomérne čistého escitalopramu a farmaceutický prostriedok s obsahom escitalopramu
RU2004105263A (ru) Фармацевтические композиции, содержащие тербинафин, и их применение
EP4520394A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
CZ291941B6 (cs) Farmaceutické kombinace obsahující tramadol
JP2013536837A5 (cg-RX-API-DMAC10.html)
EP1896076A2 (en) Compositions and methods for enhancement of sexual function
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
JP2021530568A5 (cg-RX-API-DMAC10.html)
CA2625835A1 (en) Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20110117070A1 (en) Compositions and methods for treating headache
JP7312286B2 (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体
JP2024506041A5 (cg-RX-API-DMAC10.html)
WO2020168337A4 (en) Compositions and methods for treatment of depression and other disorders
UA112652C2 (uk) Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції
JP2025505294A5 (cg-RX-API-DMAC10.html)